Begin typing your search above and press return to search.
proflie-avatar
Login
exit_to_app
DEEP READ
Munambam Waqf issue decoded
access_time 16 Nov 2024 10:48 PM IST
Ukraine
access_time 16 Aug 2023 11:16 AM IST
Foreign espionage in the UK
access_time 22 Oct 2024 2:08 PM IST
Netanyahu: the world’s Number 1 terrorist
access_time 5 Oct 2024 11:31 AM IST
exit_to_app
Homechevron_rightLifestylechevron_rightHealthchevron_rightNepal suspends sales...

Nepal suspends sales of antibiotic injection from India, citing serious health issues

text_fields
bookmark_border
Nepal suspends sales of antibiotic injection from India, citing serious health issues
cancel

The Department of Drug Administration in Nepal has suspended the sales and distribution of the antibiotic injection Biotax 1gm, manufactured by Zydus Healthcare Ltd., India, following rigorous testing that revealed serious deviations from production specifications.

The affected batch, F300460, failed to meet safety standards in Nepali laboratories, prompting regulatory intervention.

Spokesperson for the Department of Drug Administration, emphasized the gravity of the findings, citing potential risks to patients' lives posed by the non-compliant antibiotic, The Wire reported.

While specific details of the issues detected were not disclosed pending further investigation, the spokesperson assured the public that alternative medications of similar composition, from different manufacturers, remain available in the market without disruption to patient treatment.

The Department has instructed Zydus Healthcare Ltd., along with importers and distributors, to cease all sales, imports, and distributions of Biotax 1gm until further notice. Further actions against the manufacturer will be determined upon completion of the investigation into the batch's quality and safety concerns.

Show Full Article
TAGS:Biotax 1gmDepartment of Drug AdministrationZydus Healthcare Ltd
Next Story